Olopatadine suppresses the late phase reaction in parthenium dermatitis.
Anju
A
Raj
Chembolli
C
Lakshmi
C R
CR
Srinivas
D017449:Dermatitis, Allergic Contact / Q000097:blood / Q000188:drug therapy*; D003990:Dibenzoxepins / Q000627:therapeutic use*; D039563:Histamine H1 Antagonists, Non-Sedating / Q000627:therapeutic use*; D006801:Humans; D007073:Immunoglobulin E / Q000097:blood; D008297:Male; D000069605:Olopatadine Hydrochloride; D010328:Patch Tests; D020903:Tanacetum parthenium
D003990:Dibenzoxepins; D039563:Histamine H1 Antagonists, Non-Sedating; D000069605:Olopatadine Hydrochloride; D007073:Immunoglobulin E